Sotagliflozin FDA:FDA Approves Sotagliflozin
FDA Approves Sotagliflozin
2023年5月27日—TheFDAlateFridayapprovedsotagliflozin,thefirstdualsodium-glucosecotransporter1and2(SGLT1/2)inhibitor,forthetreatmentof ...。其他文章還包含有:「DualSGLT1andSGLT2inhibitorsotagliflozinachieves...」、「FDAApprovesSotagliflozinforTreatmentofHeartFailure」、「FDAUpdate」、「Inpefa(sotagliflozin)FDAApprovalHistory」、「Inpefa(sotagliflozin)tablets」、「INPEFATM(sotagliflozin)tablets」...
查看更多 離開網站Dual SGLT1 and SGLT2 inhibitor sotagliflozin achieves ...
https://www.nature.com
The FDA has approved sotagliflozin for the reduction of major heart-failure events in patients with and or diabetes, an indication that closely ...
FDA Approves Sotagliflozin for Treatment of Heart Failure
https://www.hcplive.com
The FDA approval of sotagliflozin (Inpefa) for the treatment of heart failure was announced by Lexicon Pharmaceuticals on May 26, 2023.
FDA Update
https://www.acc.org
The once-daily oral tablet is approved to reduce the risk of cardiovascular death, hospitalization for HF, and urgent HF visits in adult ...
Inpefa (sotagliflozin) FDA Approval History
https://www.drugs.com
Inpefa (sotagliflozin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the treatment of heart failure.
Inpefa (sotagliflozin) tablets
https://www.accessdata.fda.gov
for Inpefa (sotagliflozin) tablets. This NDA provides for the use of ... Form FDA 2253 is available at FDA.gov.4. Information and Instructions ...
INPEFATM (sotagliflozin) tablets
https://www.accessdata.fda.gov
See 17 for PATIENT COUNSELING INFORMATION and. FDA-approved Medication Guide. Revised: 05/2023. FULL PRESCRIBING INFORMATION: CONTENTS*. 1 INDICATIONS AND USAGE.
Sotagliflozin Gets FDA Approval in HF Across EF Spectrum
https://www.tctmd.com
The US Food and Drug Administration has approved sotagliflozin for the prevention of cardiovascular death, hospitalization for heart failure (HF) ...
禮來!FDA批准糖尿病藥SGLT12雙重抑制劑治療心衰竭
https://news.gbimonthly.com
Sotagliflozin是首個用於治療第1型和第2型糖尿病的SGLT2與SGLT1雙重抑制劑。該藥是由Lexicon與賽諾菲(Sanofi)共同合作開發,但在2019年,由於多項臨床試驗 ...